Telemedical Coaching for Weight Loss

TeleLifestyleCoaching Study - Telemedical Coaching for Weight Loss

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01837134

Acronym

Fit

Enrollment

100

Registered

2013-04-22

Start date

2013-05-31

Completion date

2014-04-30

Last updated

2014-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic Syndrome, Obesity, Overweight

Keywords

telemedicine, overweight, obesity

Brief summary

Lifestyle changes often fail due to loss of motivation. Telemedicine and personal coaching have the potential to support lifestyle change and weight loss. Therefore, the aim of our randomized controlled trial is to examine the effect of telemedicine with and without coaching in comparison to a control group on weight loss in overweight participants.

Detailed description

In an occupational health care setting employees with overweight and/or metabolic syndrome will be randomized into a three arm 12-week trial. Participants in the telemedical (TM) and telemedical coaching (TMC) group got a weighing machine and a step counter, with automatic transfer into a personalized online portal, which could be monitored from both, the participant and the study centre. The TMC group weekly will get care calls from the study centre aiming to discuss measured data and to fix target agreements. The control group will remain in routine care.

Interventions

DEVICEtelemedical (TM) group

telemedical devices (weighing machine and step counter)

BEHAVIORALtelemedical coaching (TMC) group

care calls once per week for 12 weeks

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

40 Years to 70 Years

Healthy volunteers

Yes

Inclusion criteria

* employed at Boehringer Ingelheim Pharma GmbH for at least 2 years * older than 40 years * overweight or obese or metabolic syndrome

Exclusion criteria

* not willing to participate

Design outcomes

Primary

Measure	Time frame	Description
weight loss	12 weeks	Weight will be measured at baseline and after 12 weeks.

Secondary

Measure	Time frame	Description
cardiometabolic risk factors	12 weeks	—
quality of life	12 weeks	Quality of life will be assessed by the validated questionnaires ADS-L and SF-12.
physical activity	12 weeks	Physical activity will be assessed using a validated questionnaire.

Other

Measure	Time frame	Description
eating behaviour	12 weeks	Eating behaviour will be measured using the validated questionnaire FEV.

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 21, 2026